Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study

• PR expression status correlates with overall survival in endometrioid grade 3 and endometrial serous carcinoma.
• PR expression could be used for prognostication in low stage endometrial serous carcinomas.
• Hormonal therapy may be considered in recurrent PR expressing endometrioid grade 3 carcinomas.

ObjectiveTo assess the association of hormone receptor expression with outcome in high-grade endometrial carcinomas.MethodsThis study included three sites participating in the Canadian High Risk Endometrial Cancer (CHREC) consortium. Sections from tissue microarrays containing cases with a diagnosis of endometrioid grade 3 (EC3) and endometrial serous carcinoma (ESC) were assessed for estrogen (ER) and progesterone receptor (PR) expression by immunohistochemistry. Expression was considered present if > 1% of tumor cell nuclei were labeled. Associations with overall survival were assessed.ResultsER expression was present in 168/216 (78%) of EC3 and 124/192 (65%) of ESC. PR expression was present in 148/212 (70%) of EC3 and 83/196 (42%) of ESC.PR expression was significantly associated with favorable overall survival in EC3 and ESC (log rank, p = 0.018 and p = 0.0024) but ER expression was not. PR expression was significantly associated with favorable overall survival in EC3 independent of age, stage, center and lymph-vascular invasion (hazard ratio = 0.457, 95% CI 0.257–0.811, p = 0.0075) as well as in stage I and II ESC (hazard ratio = 0.266, 95% CI 0.094–0.750, p = 0.0123).ConclusionOur data provide support for the assessment of the PR expression status in EC3 and ESC. Future work will be required to determine how PR expression may be incorporated into management of patients with EC3 and ESC.